SpringWorks Therapeutics Inc
NASDAQ:SWTX
SpringWorks Therapeutics Inc
Gross Profit
SpringWorks Therapeutics Inc
Gross Profit Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
SpringWorks Therapeutics Inc
NASDAQ:SWTX
|
Gross Profit
$179m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Gross Profit
$39.4B
|
CAGR 3-Years
0%
|
CAGR 5-Years
9%
|
CAGR 10-Years
10%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Gross Profit
$22.5B
|
CAGR 3-Years
3%
|
CAGR 5-Years
5%
|
CAGR 10-Years
1%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Gross Profit
$20.6B
|
CAGR 3-Years
2%
|
CAGR 5-Years
2%
|
CAGR 10-Years
3%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Gross Profit
$9.5B
|
CAGR 3-Years
12%
|
CAGR 5-Years
21%
|
CAGR 10-Years
34%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Gross Profit
$12.4B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
12%
|
CAGR 10-Years
17%
|
|
SpringWorks Therapeutics Inc
Glance View
SpringWorks Therapeutics Inc., a cutting-edge biopharmaceutical company, emerged from its inception as a strategic spin-out venture from the global pharmaceutical giant Pfizer. Born in 2017, the company cleverly positions itself at the forefront of the drug development process, with a keen focus on targeting rare diseases and cancer. SpringWorks leverages its robust pipeline of therapies, specifically designed to address significant unmet medical needs. Their approach revolves around the repurposing and reinvigoration of underappreciated and overlooked clinical molecules, which previously lacked the necessary backing to reach the market. This innovative approach allows SpringWorks to harness upstream R&D efforts while minimizing the typical time and resources required for de novo drug development. Earning its stripes in the field, SpringWorks generates revenue primarily through milestone and royalty agreements tied to its partnerships and co-development collaborations. Rather than relying solely on traditional sales of approved drugs, the company emphasizes strategic alliances with research institutions and pharmaceutical partners to advance its drug candidates. This co-development model extends its reach and augments the company's research capabilities, enabling SpringWorks to share risks and tap into broader resources. By nurturing innovations through collaboration, SpringWorks not only enriches its pipeline but also stands as a vanguard in transforming potential therapies into commercial realities, ultimately positioning itself as a linchpin in the orphan disease market.
See Also
What is SpringWorks Therapeutics Inc's Gross Profit?
Gross Profit
179m
USD
Based on the financial report for Dec 31, 2024, SpringWorks Therapeutics Inc's Gross Profit amounts to 179m USD.
What is SpringWorks Therapeutics Inc's Gross Profit growth rate?
Gross Profit CAGR 1Y
3 463%
Over the last year, the Gross Profit growth was 3 463%.
You don't have any saved screeners yet